The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence
Abstract
OBJECTIVE: Buprenorphine maintenance treatment (BMT) and methadone maintenance treatment (MMT) are pharmacological treatment programs for individuals with opioid use disorders. MMT is discussed in a companion article. This article describes BMT and reviews available research on its efficacy. METHODS: Authors reviewed meta-analyses, systematic reviews, and individual studies of BMT from 1995 through 2012. Databases surveyed were PubMed, PsycINFO, Applied Social Sciences Index and Abstracts, Sociological Abstracts, Social Services Abstracts, and Published International Literature on Traumatic Stress. They chose from three levels of evidence (high, moderate, and low) based on benchmarks for the number of studies and quality of their methodology. They also described the evidence of service effectiveness. RESULTS: Sixteen adequately designed randomized controlled trials of BMT indicated a high level of evidence for its positive impact on treatment retention and illicit opioid use. Seven reviews or meta-analyses were also included. When the medication was dosed adequately, BMT and MMT showed similar reduction in illicit opioid use, but BMT was associated with less risk of adverse events. Results suggested better treatment retention with MMT. BMT was associated with improved maternal and fetal outcomes in pregnancy, compared with no medication-assisted treatment. Rates of neonatal abstinence syndrome were similar for mothers treated with BMT and MMT during pregnancy, but symptoms were less severe for infants whose mothers were treated with BMT. CONCLUSIONS: BMT is associated with improved outcomes compared with placebo for individuals and pregnant women with opioid use disorders. BMT should be considered for inclusion as a covered benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Kocherlakota, P. (2014) · Pediatrics · doi:10.1542/peds.2013-3524 · Cited by 612
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 3×
“, 2003 (17) RCT to compare 4 weeks of office-based treatment with daily sublingual tablets of buprenorphine (16 mg) in combination with naloxone (4 mg), buprenorphine alone (16 mg), or placebo for patients addicted to opioids 323 patients receiving at least one dose of study medication; 109 randomly assigned to the co…”
BackgroundMethodWeiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · cited 3×
“, 2003 (15) RCT to compare daily buprenorphine (fixed dose) versus a 6-day tapered regimen of buprenorphine followed by placebo; 12-month program combined with psychotherapy 40 patients randomly assigned to fixeddose buprenorphine (N=20) or the tapered regimen (N=20) Primary: 1-year retention in treatment and negative…”
BackgroundInfluentialBuprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 3×
“Ling et al., 1998 (16) RCT to evaluate safety and efficacy of an 8 mg per day sublingual dose of buprenorphine versus a 1 mg per day dose over a 16-week treatment period in a heroin-dependent population; secondary analysis of 2 other dose levels (4 mg and 16 mg) 736 total patients in 4 dose groups:…”
BackgroundInfluentialA Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366 · cited 4×
“, 1996 (19) RCT to evaluate safety and efficacy of longterm, fixed-dose BMT versus low- and highdose MMT 225 treatment-seeking patients with opioid dependence randomly assigned to receive 8 mg per day of buprenorphine, 30 mg per day of methadone (low dose), or 80 mg of MMT (high dose), all over a 1year period Primary:…”
BackgroundMethodInfluentialAn analysis of the root causes for opioid-related overdose deaths in the United States
Webster, L. R., Cochella, S., Dasgupta, N., Fakata, K. L., Fine, P. G., Fishman, S. M., Grey, T., Johnson, E. M., Lee, L. K., Passik, S. D., et al. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01134.x · Cited by 295
A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence
Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150 · cited 5×
“, 2001 (36) Compare the effectiveness of buprenorphine and of methadone Patients receiving methadone at medium-high (50– 80 mg) and low (20–35 mg) doses and buprenorphine at medium doses (6–12 mg) across 5 RCTs Primary: retention in treatment and urine drug screens for opioids Compared with patients on medium-high met…”
BackgroundResultInfluential
Cited by
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
“…a reduction in mortality, with a similar risk across all time in treatment (about four deaths/1000 person years) consistent with its safety profile, 39-44 and a risk after cessation higher in the first four weeks than in the remainder of time out of treatment (32 versus 11 deaths/1000 person…”
BackgroundManagement of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004–2014
Winkelman, T. N. A., Villapiano, N., Kozhimannil, K. B., Davis, M. M., & Patrick, S. W. (2018) · Pediatrics · doi:10.1542/peds.2017-3520 · Cited by 373
Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019) · The Journal of Rural Health · doi:10.1111/jrh.12307 · Cited by 311
Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10386 · Cited by 222
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Carroll, K. M., & Weiss, R. D. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16070792 · Cited by 211
“Numerous reviews and meta-analyses underscore the effectiveness of buprenorphine in enhancing treatment retention and reducing illicit opioid use compared with placebo or no treatment (13, 14).”
BackgroundDiscontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Comorbidity of opioid-related and anxiety-related symptoms and disorders
Langdon, K. J., Dove, K., & Ramsey, S. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2018.12.020 · Cited by 53
Reif, S., Brolin, M. F., Stewart, M. T., Fuchs, T. J., Speaker, E., & Mazel, S. B. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.07.007 · Cited by 58
Kennedy, D. P., Osilla, K. C., Hunter, S. B., Golinelli, D., Maksabedian Hernandez, E., & Tucker, J. S. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.12.005 · Cited by 40
Metadata
- Authors
- Thomas, C. P., Fullerton, C. A., Kim, M., Montejano, L., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E.
- Venue
- Psychiatric Services
- Published
- 2014-02
- Volume
- 65
- Issue
- 2
- Pages
- 158-170
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2146443350
- Cited by
- 208
- References
- 11
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.